AN0025 (Palupiprant)

AN0025 is an investigational, potentially first-in-class oral EP4 antagonist that blocks prostaglandin E2 from binding to its subtype 4 receptor (EP4) changing the immunosuppressive character of the tumor microenvironment. Based on preliminary results, it is well tolerated in patients with solid tumors. 


A phase 1b study of AN0025 in combination with the standard of care in a neoadjuvant setting for locally advanced rectal cancer showed excellent results, with nearly 40% of patients not requiring surgery or achieving a complete pathological response in the post-surgical specimen in this study. 


The first patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metastatic solid tumors.


 Mechanism of Action
Latest progress
Patients have begun dosing in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metastatic solid tumors.
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 at ESMO 2019. With nearly 40% of patients not requiring surgery or achieving a complete pathological response in the post-surgical specimen in this study, AN0025 in combination with the standard pre-operative treatment warrants further development.
About Rectal Cancer

Rectal cancer is a disease in which malignant (cancer) cells form in the tissues of the rectum. Rectal cancer treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and active surveillance. Surgery is the most common treatment for all stages of rectal cancer. Radiation therapy and/or chemotherapy may be given before surgery to shrink the tumor, make it easier to remove the cancer, and help with bowel control after surgery. Treatment given before surgery is called neoadjuvant therapy.